Pro-Vice-Chancellor Karin Dahlman Wright

Denna sida på svenska

Phone: +46 8 524 867 64
Visiting address: Nobels väg 6, Solna

About me

I am professor of molecular endocrinology and was made pro-vice-chancellor of Karolinska Institutet on 1 January 2016. On 18 February that same year, the government appointed me Karolinska Institutet’s acting vice-chancellor, a position I relinquished on 1 August 2017 to resume my previous title. From 2009 until August 2015 I was head of the Department of Biosciences and Nutrition, and in 2015 I was vice-dean of infrastructure.

Between September 2013 and June 2015 I was KI Scientific Director at SciLifeLab with special responsibility for the national platforms, and was a member of SciLifeLab’s operational management. In 2001 I founded BEA, a core facility that provides advanced services in genomics and bioinformatics. From 1994 to 2000 I held the positions of line manager and project manager at Pharmacia and Upjohn. I am also active in the Strategic Research Area in Diabetes at KI.

Selected publications

Expression of sex steroid hormone receptors in human skeletal muscle during the menstrual cycle.
Ekenros L, Papoutsi Z, Fridén C, Dahlman Wright K, Lindén Hirschberg A
Acta Physiol (Oxf) 2017 Feb;219(2):486-493

Altered DNA methylation of glycolytic and lipogenic genes in liver from obese and type 2 diabetic patients.
Kirchner H, Sinha I, Gao H, Ruby M, Schönke M, Lindvall J, et al
Mol Metab 2016 Mar;5(3):171-83

AP-1 Is a Key Regulator of Proinflammatory Cytokine TNFα-mediated Triple-negative Breast Cancer Progression.
Qiao Y, He H, Jonsson P, Sinha I, Zhao C, Dahlman-Wright K
J. Biol. Chem. 2016 Mar;291(10):5068-79

Blockade of the Hedgehog pathway downregulates estrogen receptor alpha signaling in breast cancer cells.
Diao Y, Azatyan A, Rahman M, Zhao C, Zhu J, Dahlman-Wright K, et al
Oncotarget 2016 Nov;7(44):71580-71593

Differential methylation in inflammation and type 2 diabetes genes in siblings born before and after maternal bariatric surgery.
Berglind D, Müller P, Willmer M, Sinha I, Tynelius P, Näslund E, et al
Obesity (Silver Spring) 2016 Jan;24(1):250-61

Estrogen Enhances the Expression of the Polyunsaturated Fatty Acid Elongase Elovl2 via ERα in Breast Cancer Cells.
González-Bengtsson A, Asadi A, Gao H, Dahlman-Wright K, Jacobsson A
PLoS ONE 2016 ;11(10):e0164241

Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism.
Jia M, Andreassen T, Jensen L, Bathen T, Sinha I, Gao H, et al
Cancer Res. 2016 Oct;76(19):5634-5646

RING finger protein 31 promotes p53 degradation in breast cancer cells.
Zhu J, Zhao C, Zhuang T, Jonsson P, Sinha I, Williams C, et al
Oncogene 2016 Apr;35(15):1955-64

Peroxisome Proliferator-activated Receptor γ Coactivator-1 α Isoforms Selectively Regulate Multiple Splicing Events on Target Genes.
Martínez-Redondo V, Jannig P, Correia J, Ferreira D, Cervenka I, Lindvall J, et al
J. Biol. Chem. 2016 07;291(29):15169-84

All publications

Commission of trust

I am a member of the SciLifeLab Stockholm steering board and the joint steering committee for AstraZeneca/KI/ SciLifeLab collaboration. I am also a member of the reference group for the European spallation resource ESS I have acted as Chairman, vice Chairman and member of evaluation panels at the Swedish Research Council. I have evaluated research in Norway on request of the Norwegian Research Council. 2007-2008 and 2015-, I was a member of the KI-SLL infrastructure council. I have taken part in a committee on behalf of the Swedish department of justice with regard to patents in the area of biotechnology and I am appointed expert in patent cases.


Ph.D Medical Sciences, Karolinska Institutet, 1991

Docent Molecular Endocrinology, Karolinska Institutet, 1996

Research description

My research is focused on studies of estrogen signaling with specific focus on type 2 diabetes and breast cancer. We study phenotypes of mouse models with tissue selective knock-out of estrogen receptors and relate this to molecular changes such as changes in global gene expression. We use different breast cancer cell models and functional genomics technologies, such as ChIP SEQ, global gene expression analysis and proteomics, to identify signaling pathways that can include possible targets for treatment of breast cancer.

More information about my research at the Department of Biosciences and Nutrition